Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
8 hedge funds and large institutions have $492K invested in Avenue Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
21% more capital invested
Capital invested by funds: $407K → $492K (+$84.6K)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
11% less funds holding
Funds holding: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$115K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$73.6K |
| 3 |
MAWA
Moss Adams Wealth Advisors
Seattle,
Washington
|
+$31.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$15.7K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $286K | +$115K | +40,000 | +53% |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $157K | +$73.6K | +25,666 | +69% |
|
|
MAWA
3
Moss Adams Wealth Advisors
Seattle,
Washington
| $27.4K | +$31.5K | +11,000 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $15.3K | +$15.7K | +5,470 | +813% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $4.33K | -$4.2K | -1,465 | -46% |
|
|
6
Wells Fargo
San Francisco,
California
| $1.4K | +$1.43K | +500 | +820% |
|
7
Bank of America
Charlotte,
North Carolina
| $25 | +$9 | +3 | +43% |
|
8
JP Morgan Chase
New York
| $3 | – | – | – |
|
ATXI Hedge Fund Activity: Q3 2024 in Review
8 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q3 2024, worth a combined $492K — up 21% from $407K a quarter earlier.
Fund positioning in ATXI was balanced in Q3 2024: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $115K. The largest seller was Tower Research Capital (TRC), cutting an estimated $4.2K.
- 8 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q3 2024, down from 9 in Q2 2024.
- Funds reported $492K of Avenue Therapeutics, Inc. Common Stock stock for Q3 2024, up 21% quarter-over-quarter.
- 1 fund opened new Avenue Therapeutics, Inc. Common Stock positions in Q3 2024 and 1 closed out, a net change of 0 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q3 2024 was Armistice Capital, an estimated $115K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q3 2024 was Tower Research Capital (TRC), an estimated $4.2K sold.
Based on aggregated 13F filings for Q3 2024.